Head-to-head evidence
Budesonide (Uceris rectal foam) vs hydrocortisone acetate (Cortifoam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: Glucocorticoid receptor · full Ulcerative Colitis pipeline
Budesonide (Uceris rectal foam)
Marketed by Bausch Health
NCT01008423 · Phase 3 · completed
The study was a randomized, triple-blind, placebo-controlled trial with 134 participants receiving budesonide and 147 receiving placebo. Its primary endpoint was a clinical-and-endoscopic remission measure, and the comparison significantly favored budesonide at week 6 (44.0% vs 22.4%, p<0.0001).
hydrocortisone acetate (Cortifoam)
Marketed by Viatris
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Budesonide (Uceris rectal foam)'s landscape · hydrocortisone acetate (Cortifoam)'s landscape